Drug intelligence / Profile preview

jiannao tongluo

Development stage: Unknown
Lead developer: Hubei Xinhua Hospital
Administration: Oral

Overview

Jiannao Tongluo is a Traditional Chinese Medicine (TCM) herbal formulation, typically administered as granules, developed for the treatment of convalescent cerebral infarction. It is specifically indicated for patients presenting with the TCM syndromes of wind-phlegm and blood stasis. The formulation aims to improve neurological function and promote recovery following a stroke by addressing these underlying pathological factors. It is being studied by the Hubei Provincial Hospital of Integrated Chinese and Western Medicine (also known as Xinhua Hospital Affiliated to Hubei University of Traditional Chinese Medicine).

Brand names: jiannao tongluo granules
Other names: Jiannao Tongluo Granules

Beyond the preview

Go deeper on jiannao tongluo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jiannao tongluo.

Explore the full profile